Iteos Therapeutics Inc

NASDAQ:ITOSUnited States

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.

Contact Information

Headquarters

321 Arsenal Street Bldg 312, Floor 3, Suite 301WATERTOWN, MA, United States 02472

Phone

857-204-4583

Fax

302-655-5049

Executives

Non-Executive Independent Chairman of the Board

David Hallal

President, Chief Executive Officer, Director

Michel Detheux

Chief Financial Officer

Matthew Gall

Chief Operating Officer

Matthew Call

Chief Scientific Officer

Yvonne Mcgrath